Pediatric therapeutic-protein PBPK scaling
A reduced pediatric PBPK model connecting body-size-dependent antibody disposition to central and peripheral exposure and optional target binding.
- Therapeutic
- Palivizumab or bevacizumab, palivizumab; bevacizumab
- Target
- RSV F protein, VEGFA, FcRn
- Disease
- Pediatric therapeutic-protein dose and exposure scaling
Biological model
A reduced pediatric PBPK model connecting body-size-dependent antibody disposition to central and peripheral exposure and optional target binding.
Model details
A reduced pediatric PBPK model connecting body-size-dependent antibody disposition to central and peripheral exposure and optional target binding.
Modeled states
- AUC ug ml dayug/mL*day
Modeled dynamic state for auc ug ml day.
- A central mgmg
Modeled dynamic state for a central mg.
- A peripheral mgmg
Modeled dynamic state for a peripheral mg.
- complex uMuM
Modeled dynamic state for complex um.
- elapsed time dayday
Modeled dynamic state for elapsed time day.
- target free uMuM
Modeled dynamic state for target free um.
Key readouts
- Central antibody concentrationunknown
Model-derived readout for central antibody concentration.
- Peripheral antibody concentrationunknown
Model-derived readout for peripheral antibody concentration.
- Free targetuM
Model-derived readout for free target.
- Drug–target complexuM
Model-derived readout for drug–target complex.
- Cumulative exposureug/mL*day
Model-derived readout for cumulative exposure.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Palivizumab 15 mg/kg nominal-age growth
How does pediatric growth change therapeutic-protein disposition, exposure, and target binding? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Free target, Drug–target complex, Cumulative exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does pediatric growth change therapeutic-protein disposition, exposure, and target binding?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does pediatric growth change therapeutic-protein disposition, exposure, and target binding?
body weight kg
Model parameter controlling body weight kg.
Exploratory range around the default value.
5 evenly spaced values in kg. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-SimFrontiers in Pharmacology
